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intravitreal bevacizumab for macular edema due 
to branch retinal vein occlusion: 12-month results
Purpose: To present the functional and anatomic changes after intravitreal bevacizumab in 
eyes with macular edema (ME) due to branch retinal vein occlusion (BRVO).
Design: The study was a retrospective study.
Materials and methods: The study included 31 patients with ME due to BRVO. We 
  compared the examination findings of patients with ME before and after intravitreal bevaci-
zumab therapy at 12 months. The study included patients who had macular edema secondary 
to BRVO treated with bevacizumab. The therapy was started in the first week after occlusion. 
The initial therapy was three intravitreal bevacizumab injections at monthly intervals with 
1.25/0.05 mL bevacizumab. Patients with a baseline visual acuity less than 0.5 (logarithm of 
the minimum angle of resolution [logMAR] 0.30), central macular thickness (CMT) more than 
290 µm, and no neovascularization were included. Patients with diabetes mellitus or a history 
of intravitreal triamcinolone or grid laser photocoagulation therapy or ischemic BRVO were 
excluded. The retreatment criteria were as follows: increased CMT more than 100 µm com-
bined with a loss of visual acuity of five or more letters. The statistical analysis of this study 
was carried out by paired samples t-test (SPSS). A P value of less than 0.05 was considered 
to be statistically significant.
Results: This retrospective study included 33 eyes of 31 patients (20 women, 11 men; mean age 
was 55.30 ± 9.62 years (range 36–75 years). Patients received a mean of 5.3 injections during 
12 months of follow-up. The best corrected visual acuity increased from 0.66 ± 0.20 (logMAR) 
at baseline to 0.22 ± 0.13 (logMAR) (t = 15.42; P , 0.001) at month 12. The CMT decreased 
from 494.15 ± 104.16 µm at baseline to 261.79 ± 45.36 µm at month 12 (−232.36 ± 109.98 µm); 
P , 0.001). No bevacizumab-related systemic or ocular adverse effects following intravitreal 
drug injections were observed. The majority of patients required reinjection(s) treatment for 
ME (84.9%).
Conclusion: Intravitreal therapy using bevacizumab appears to be an effective primary 
treatment option for ME due to BRVO. No serious ophthalmologic or systemic side effects 
were observed for intravitreal bevacizumab therapy. The main disadvantage of bevacizumab 
therapy is the requirement of multiple injections in order to maintain visual and anatomic 
improvements.
Keywords: branch retinal vein occlusion, macular edema, intravitreal bevacizumab injection, 
central macular thickness, visual acuity
Introduction
Retinal vein occlusion (RVO) is the most common retinal vascular disease after diabetic 
retinopathy. Although the pathogenesis is still not fully clear, several risk factors have 
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been associated with RVO, including age, diabetes mellitus, 
atherosclerotic retinal vessel changes, hypertension, and 
open-angle glaucoma.1–4
The most common sequela of branch retinal vein occlusion 
(BRVO) is the development of cystoid macular edema (ME) 
with a consecutive deterioration in vision. The major stimulus 
for the formation of ME and neovascularization in patients 
with RVO seems to be hypoxia-induced production of vascular 
endothelial growth factor (VEGF), an angiogenic factor that 
promotes angiogenesis and increases vascular permeability.5
The only proven treatment method for eyes with ME 
secondary to BRVO is macular grid laser photocoagulation. 
However, according to the Branch Vein Occlusion Study 
(BVOS), only patients with ME associated with BRVO and 
a visual acuity of 20/40 or less showed a significant visual 
benefit compared with the untreated control group.6
An alternative therapy for patients with ME secondary to 
BRVO is intravitreal anti-VEGF injection. The first report 
of the efficacy of intravitreal bevacizumab (a recombinant 
monoclonal antibbody binding to all isoforms of VEGF) in 
a patient with ME secondary to BRVO was in 2005.7
Several studies have evaluated the efficacy of intravitreal 
triamcinolone in the treatment of ME secondary to BRVO, 
but were only able to show stabilization or a moderate 
improvement in visual acuity.8–10 However, the main limita-
tion of intravitreal triamcinolone therapy is the high rate of 
side effects, such as cataract formation or increased intraocu-
lar pressure. No complications or serious side effects were 
observed in recent studies of bevacizumab therapy.11–14
Several retrospective and prospective studies have shown 
the benefit of anti-VEGF treatment, with an improvement in 
visual acuity and a decrease of retinal thickness in patients 
with ME associated with RVO.11–13,15–22
We have designed a retrospective clinical study to pres-
ent the effect of intravitreal bevacizumab therapy in patients 
with ME secondary to BRVO at 12 months.
We reviewed data of patients who had ME secondary 
to BRVO who were treated with bevacizumab (Avastin 
1.25 mg/0.05 mL) and followed up with regular visits (every 
month) during at least 12 months.
Materials and methods
The study included 31 patients with ME secondary to BRVO. 
The inclusion criteria were: ME secondary to BRVO, 
  initial   therapy started in the first week with Avastin, a baseline 
visual acuity below 0.5 (logarithm of the minimum angle of reso-
lution [logMAR] 0.3), central macular thickness (CMT) more 
than 290 µm, and no neovascularization. Patients with diabetes 
mellitus, a history of intravitreal triamcinolone injection(s) or 
grid laser photocoagulation therapy, or ischemic BRVO were 
excluded from this study. All eyes had a complete ophthal-
mologic evaluation at baseline, day 1, day 7, month 1, and at 
monthly intervals during follow-up. Examinations included best 
corrected visual acuity (BCVA); testing using Early Treatment 
Diabetic Retinopathy Study (ETDRS) charts at 4 meters in the 
logMAR values; slit-lamp and fundus examination, including 
tonometry; standardized optical cohorence tomography imag-
ing (OCT) (Optovue, Inc Freemont, CA); and color fundus 
  photography. Fluorescein angiography was performed at base-
line and at 12 months to identify the presence of BRVO, active 
extravasation, and the extent of retinal nonperfusion.
All patients received three initial Avastin (bevacizumab 
1.25 mg/0.05 mL) injections at monthly intervals. Patients 
were examined monthly after three injections. The retreatment 
was performed when there was an increase in 1 mm CMT as 
measured by OCT macular mapping of at least 100 µm with/
without a vision loss for at least five ETDRS letters.
All intravitreal injections were performed in the operating 
room under sterile conditions. Bevacizumab was filled and 
packed under sterile conditions by the institutional phar-
macy, using tuberculine syringes containing a total volume 
1.25 mg/0.05 mL. Avastin was injected into vitreous body 
via pars plana using a 27 G needle at inferior temporal area 
at 3.5 mm distance from limbus. The visual acuity and mean 
CMT are expressed as mean ± standard deviation. The data 
at baseline and after injections at 12 months were evalu-
ated statistically. The statistical analysis of this study was 
carried out by the paired samples t-test (SPSS; SPSS, Inc., 
Chicago, IL). A P value of less than 0.05 was considered to 
be statistically significant.
Results
This retrospective study included 33 eyes of 31 patients 
(20 women, 11 men; mean age was 55.30 ± 9.62 years (range 
36–75 years). The frequency of bevacizumab injections into 
vitreous body is presented in Table 1.
The mean BCVA was 0.66 ± 0.20 LogMAR at base-
line and improved to 0.22 ± 0.13 LogMAR at 12 weeks; 
Table 1 Distribution of number of reinjections
Injections n (eyes)  %
3 5   15.1
4–5 13   39.4
6–7 13   39.4
8 2   6.1
Total 33  100Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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the mean 1 mm CMT was 494.15 ± 104.16 µm (range 
343–771).
After 12 months of follow-up, the mean logMAR val-
ues of BCVA had increased significantly to 0.66 ± 0.20 
(t = 15.42; P , 0.001), whereas mean CMT had decreased to 
261.79 ± 45.36 µm (−232.36 ± 109.98 µm; P , 0.001) (Figure 1).
No major ophthalmologic (retinal detachment, ocular 
hypertension, glaucoma, uveitis, endopthalmitis, retinal 
artery occlusion) or systemic (thromboembolic events, 
systemic hypertension, myocardial infarction) side effects 
occurred. Neovascularization of the retina, optic disc, or iris 
have not been recorded.
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A 46- year old woman, she had left BRVO, baseline visual acuity 0.1, CMT was 771 µm.
Bevacizumab was started within 2 days.
After 3 injections visual acuity was 0.3 and CMT was 379 µm.
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CMT was 257 µm.
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Figure 1 The result of bevacizumab therapy in a patient with macular edema secondary to branch retinal vein occlusion (BrVO). A 46-year-old woman had left BrVO, 
baseline visual acuity of 0.1, and central macular thickness (CMT) of 771 µm. Bevacizumab was started within 2 days. After three injections, visual acuity was 0.3 and CMT 
was 379. she had received eight injections at 12 months. After eight injections at 12 months, her visual acuity was 0.5 and CMT was 257 µm.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Discussion
In this study we compared data of baseline values and after 
therapy with bevacizumab (injections 3–8) at 12 months. The 
results of this retrospective study showed that intravitreal beva-
cizumab treatment in patients with ME secondary to BRVO was 
associated with a significant improvement in visual acuity (from 
0.66 ± 0.20 to 0.22 ± 0.13 logMAR) and with a marked decrease 
in CMT (−232.36 ± 109.98 µm; P , 0.001) at 12 months.
During 12 months of follow-up, no severe ocular adverse 
effects, such as endophthalmitis, retinal detachment, trau-
matic cataract, ocular hypertension, glaucoma, uveitis, and 
central retinal artery occlusion, were observed.
We did not encounter any serious side effects related to 
bevacizumab. However, serious side effects of bevacizumab 
have been reported.15–17,23
A recent study showed that the results of therapy with 
bevacizumab were better than those with grid laser therapy 
in ME secondary to BRVO.24,25 However, cataract, ocular 
hypertension, and glaucoma are frequently encountered with 
triamcinolone therapy.26–29 We did not observe cataract or 
glaucoma in our study.
A decrease in CMT as seen by OCT and a reduction in the 
area of leakage with fluorescein angiography were observed. 
Avascular areas were stable and they did not progress after 
treatment with Avastin.
Although nearly all patients showed an important response 
to intravitreal Avastin treatment with an increase in visual 
acuity and a reduction in CMT initial therapy, the ME had not 
resolved completely in 84.9% of all patients after three injec-
tions. The majority of patients required retreatment for ME.
The main disadvantage of Avastin is short duration of the 
therapeutic effect and the requirement of reinjections.11,19,21,22 
We did not measure anti-VEGF levels, but some studies also 
showed a close correlation between aqueous VEGF levels 
and the severity of ME in patients with RVO.30,31
Finally, intravitreal bevacizumab therapy appears to be an 
effective and safe treatment option for ME secondary to BRVO. 
The main disadvantage is the requirement for multiple injections 
in order to maintain good visual acuity and macular thickness.
Disclosure
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